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INTRODUCTION  1 
Peripheral arterial disease (PAD) is the result of atherosclerotic arterial stenosis and 2 
occlusions in the larger vessels supplying the lower extremities.1 Patients with PAD have a 3 
markedly increased risk for future cardiovascular mortality and morbidity.1-4 Endothelial 4 
dysfunction contributes to the development and progression of PAD.5, 6 Endothelial function, 5 
often examined as the brachial artery reactivity response to ischaemia, in PAD patients is 6 
impaired7-9 and relates to future CV events.10, 11 The recent AHA/ACC-guideline on the 7 
management of PAD highlighted the need for an easy, simple and rapid test of endothelial 8 
function to predict future adverse events in PAD.12 Although brachial artery reactivity shows 9 
predictive capacity for future CV events,10, 11 concerns have been raised regarding practical 10 
limitations that prevents the clinical application of this technique. 11 
 12 
Carotid artery reactivity (CAR) testing is a simple, non-invasive procedure to examine 13 
endothelial function. It involves measuring the carotid artery diameter responses to the 14 
sympathetic stimulation produced by the cold pressor test (CPT).13, 14 The carotid arteries, like 15 
coronary arteries,13, 14 dilate in response to the CPT in healthy subjects, whereas this dilation 16 
is attenuated, or reversed to vasoconstriction, in patients with cardiovascular disease.13-16 17 
Interestingly, the coronary arteries’ response to CPT is a strong, independent predictor of 18 
cardiovascular events,17, 18 but it is not clear if the carotid response to CPT (i.e. CAR) also 19 
predicts future cardiovascular events. This study is to our knowledge, the first to examine the 20 
prognostic value of the CAR in patients with PAD. We hypothesized that CAR-induced 21 
vasoconstriction would predict future CV events in patients with PAD, independent of subject 22 
characteristics and clinical status. 23 
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 1 
METHODS 2 
Participants and study approval 3 
We recruited 172 patients with PAD scheduled for a routine visit at the vascular laboratory 4 
(Department of Surgery, Radboud University Medical Center, Netherlands) for the study 5 
(Figure 1). We included PAD patients with present or prior Fontaine classification 2B-3-4, 6 
age ≥18yr, and the ability to provide informed consent. We excluded patients with Raynaud's 7 
phenomenon, chronic pain syndrome, open wounds on the upper extremities, arterial-venous 8 
shunts, scleroderma, coronary, central and/or peripheral arterial disease interventions within 9 
the prior <1 week, and unstable angina pectoris, myocardial infarction, stroke or heart failure 10 
within the prior 3 months. Patients provided written informed consent prior to participation. 11 
The study was approved by the local Ethics Committee (NL-46109.091.13) in accordance 12 
with the latest revision of the Declaration of Helsinki. This study was registered as NTR-4117 13 
(Netherlands Trial Registration). 14 
 15 
Experimental design 16 
Patients abstained from strenuous exercise for 24 hours, fasted for ≥6 hours, and abstained 17 
from caffeine and vitamin C, which are known to alter endothelial function, for ≥18 hours 18 
prior to testing in accordance with guidelines on assessing endothelial function.20  19 
 20 
Experimental measures 21 
General characteristics. Age and sex were obtained from the electronic patient records. A 22 
physician obtained the history of smoking, hypercholesterolemia, hypertension, diabetes and 23 
medication use. Height (in m), weight (in kg), and waist-hip ratio (WHR) were measured by a 24 
research nurse. The same vascular surgeon assigned the patient’s Fontaine clinical 25 
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classification. Patients with Fontaine stage ≥2 performed walking tests to distinguish between 1 
Fontaine stages. Finally, the ankle-brachial pressure index (ABPI) was measured based on 2 
clinical requirements following recent guidelines.21 The highest systolic pressure in the right 3 
and left posterior tibial or dorsal pedis artery and in the right brachial artery was measured 4 
twice, and the average of those two measurements was used to calculate the ABPI for each 5 
leg. The lowest ABPI of two legs was used for analysis. For the purpose of analysis, we 6 
compared those above versus below the median ABPI.  7 
 8 
Carotid artery reactivity. Patients rested on a comfortable bed in a temperature controlled 9 
room for at least 5 minutes. Participants were in the supine position with the neck extended 10 
for assessment of the carotid artery. Left carotid artery diameter was recorded continuously 11 
for 30-seconds before and for 90-seconds during immersion of the hand up to the wrist in ice 12 
slush (4 °C). Images were obtained using a L9-3 MHz linear array probe attached to a high 13 
resolution ultrasound machine. When an optimal image was found, the probe was held stable 14 
and the ultrasound parameters were set to optimise the longitudinal, B-mode image of the 15 
lumen-arterial wall interface. Following a 30-second baseline assessment of carotid artery 16 
diameter, the hand was immersed for 90-seconds with simultaneous and continuous 17 
assessment of carotid artery diameter.  18 
CAR% responses were assessed for diameter. Analysis of the carotid artery diameter was 19 
performed by a single blinded investigator using custom-designed edge-detection and wall-20 
tracking software, which is largely independent of investigator bias.22 Details of this 21 
technique can be found elsewhere.23 Baseline diameter was calculated as the mean of data 22 
acquired across the 30 seconds preceding the CPT test. After submersion of the hand in ice 23 
slush, data were calculated as the mean value for 10-second intervals, involving 8-10 full 24 
cardiac cycles. Based on this data we calculated the peak diameter change (i.e. the 10-second 25 
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bin with the highest value, CAR%). The peak diameter change can refer to a maximum 1 
constriction or dilation. The direction of this change was determined by a positive (i.e. 2 
dilation) or negative (i.e. constriction) area under the curve.  3 
Reproducibility (coefficient of variation, CV) of diameter responses to CPT were previously 4 
assessed with a 1- and 24-hour intervals in 50 subjects. Within-day CV for baseline and peak 5 
diameters were 2.2 and 2.6%, whilst day-to-day CV were 2.3% and 2.7%. Furthermore, the 6 
CAR% (i.e. maximum change in diameter) showed a within-day reproducibility of 2.6% and 7 
between-day reproducibility of 2.8%.14  8 
 9 
Intima-media thickness. Carotid artery intima-media thickness (cIMT), a marker for vascular 10 
structure, is related to future development of PAD.24 To examine whether the CAR relates to 11 
future CV events, independent of the cIMT, we examined cIMT from the same section of the 12 
artery as the CAR. We obtained continuous recordings of the cIMT for 10 seconds. Analyses 13 
were performed by a blinded researcher, using observer-independent edge-detection and wall-14 
tracking software.25 For the purpose of analysis, we compared those above versus below the 15 
median cIMT. 16 
 17 
Follow up and assessment of adverse events 18 
After 12 months of follow-up, adverse events were extracted from medical records and 19 
verified by a blinded vascular surgeon (MW). The Dutch National Death Registration was 20 
used to determine mortality. Death certificates of patients who experienced a fatal event were 21 
obtained when available to categorise death into CV or non-CV related mortality. Adverse 22 
events were categorised into; 1. Cardio- and cerebrovascular events (“CV events”; CV-related 23 
mortality, myocardial infarction, coronary revascularisation procedures, transcranial ischemic 24 
attack, cerebrovascular accident, carotid surgery, major- and minor amputations, and ischemic 25 
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bowel disease), 2. “Clinical progression” that is related to PAD (loss of patency (i.e., the 1 
presence of restenosis in a previous endovascular reconstructed vessel), endovascular 2 
reconstructive surgery using percutaneous transluminal angioplasty, and worsening in 3 
Fontaine-classification), and 3. “All-cause Mortality”. We also grouped these 3 categories to 4 
capture all adverse events (“Adverse events”). Only the first event was included in the 5 
analyses for patients who experienced more than 1 event. All indications for PTA and 6 
revascularisation surgery were discussed prior in a multidisciplinary team of vascular 7 
surgeons and interventional radiologists, whilst preference of patient and interventional were 8 
taken into consideration. All involved members of the multidisciplinary team were blinded to 9 
the outcome of the CAR test.   10 
 11 
Statistical analysis 12 
Prior to our study, we aimed to include 200 PAD patients. This group size is in line with 13 
previous studies examining the prognostic value of measures of vascular health,10, 19 whilst 14 
this group size also accounts for potential drop out (10-15%) and access to sufficient PAD 15 
patients (n=400/annum, 50% inclusion rate). Data are presented as mean±SD or n (%) unless 16 
stated otherwise. Statistical analysis was performed using IBM SPSS Statistics 21.0 (IBM 17 
SPSS, IBM Corp., Armonk, NY, USA). Baseline characteristics were assessed for normality 18 
with the Shapiro-Wilk test. We adopted unpaired Student’s t-tests (Mann-Whitney U-test for 19 
non-normally distributed parameters) to compare subject characteristics, co-morbidities, 20 
clinical status, and medication use between PAD patients with carotid constriction vs. 21 
dilation. We used logistic regression to assess if subject characteristics, co-morbidities, 22 
clinical status, or medication could predict presence of carotid constriction. 23 
Analyses to examine whether presence of carotid constriction could predict future events, 24 
analyses were performed separately for “CV events”, “Clinical progression”, “All-cause 25 
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mortality” and “Adverse events”. Cumulative event rates of carotid constriction and dilation 1 
were estimated with Kaplan-Meier survival analyses, and were calculated with the log-rank 2 
test. Cox proportional hazard models were used to calculate hazard ratios, including 3 
correction for confounding variables (age, sex, BMI, and WHR). These variables were 4 
selected based on prior evidence of an association with measures of endothelial function.14, 20 5 
Analyses were repeated in subgroups in whom we examined cIMT (n=169) or ABPI (n=142). 6 
We examined if these clinical measures were related to increased risk for future events,26 and 7 
whether they altered the analyses related to carotid measurement. 8 
 9 
RESULTS 10 
Subject characteristics, co-morbidities, clinical status and adequate imaging was obtained in 11 
all 172 PAD patients. Median change in carotid artery diameter was 0.8% (95% Confidence 12 
Interval -19.3 – 11.6%). Carotid constriction occurred in n=82 patients, whereas vasodilation 13 
occurred in 90 patients. Seventy patients (41%) experienced ≥1 event, which included loss of 14 
patency (n=18), increase in Fontaine-classification (n=15), percutaneous transluminal 15 
angioplasty (n=44), transient ischemic attack (n=1), myocardial infarction (n=4), 16 
cerebrovascular accident (n=3), coronary revascularisation procedures (n=1), major (n=7) and 17 
minor (n=1) amputation, and ischemic bowel disease (n=1). Ten PAD patients died; from CV-18 
related mortality (n=4), cancer-related mortality (n=2), and unknown cause (n=4). We found 19 
no baseline differences between PAD patients with carotid constriction versus dilation in 20 
subject characteristics or co-morbidities. Patients with carotid constriction reported lower 21 
antiplatelet drugs usage (Table 1). Logistic regression revealed that none of the subject 22 
characteristics, co-morbidities, clinical status or medication use could predict if a PAD patient 23 
would demonstrate carotid constriction
 
(backward likelihood ratio analysis, all parameters 24 
P>0.05). When comparing patients with and without an adverse event, those with events 25 
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showed higher prevalence of hypercholesterolemia. Other factors did not differ between 1 
groups (Supplemental data 1). 2 
 3 
Prognostic value of carotid constriction for future adverse events.  4 
Kaplan-Meier survival curves demonstrated that PAD patients with carotid constriction report 5 
a higher incidence of CV events (P=0.007), clinical progression (P=0.005) and adverse events 6 
(P=0.006) compared to carotid dilation (Figure 3). There were no significant differences 7 
between groups for all-cause mortality (Log-rank, P=0.417, Figure 3).   8 
Using a multivariate Cox proportional hazard model, with the fully adjusted model correcting 9 
for potential confounders (i.e. age, sex, WHR and BMI), PAD patients with carotid 10 
constriction continued to demonstrate higher risk for CV events (HR 4.1, 95%CI 1.3-12.5), 11 
clinical progression (HR 2.0, 95%CI 1.2-3.3) and adverse events (HR 1.8, 95%CI 1.1-3.0), 12 
but not all-cause mortality (HR 1.4, 95%CI 0.4-5.1, Table 2). 13 
 14 
Added value of clinical measures. In 30 subjects, we were unable to perform a valid ABPI 15 
because of non-compressible arteries or amputation. We were unable to perform analysis of 16 
cIMT in 3 participants because of technical problems. Analyses for cIMT (n=169) and ABPI 17 
(n=142) showed no significant effect using the Kaplan-Meier survival analysis for adverse 18 
events (Figure 4), CV events (Log-rank P= 0.674 and 0.457, respectively), clinical 19 
progression (Log-rank P= 0.484 and 0.153, respectively) or all-cause mortality (Log-rank 20 
P= 0.198 and 0.795, respectively).  21 
The cox proportional hazard models for the carotid constriction (including models 1 and 2) 22 
were repeated for the subgroups with data on cIMT and ABPI. Adding cIMT or ABPI to the 23 
fully adjusted model did not alter the HR of carotid constriction for future CV events, clinical 24 
progression, all-cause mortality or adverse events (Supplemental material 2).   25 
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DISCUSSION 1 
This is the first study, to our knowledge, to examine the relation between the carotid response 2 
to the cold pressor test and future CV events in PAD patients. We found that patients who 3 
demonstrated carotid constriction during the cold pressor test had a 4.1-, 2.0- and 1.8-times 4 
increased risk at 1-year of developing a CV event, clinical deterioration and other adverse 5 
events, respectively, compared to those with carotid dilation. Importantly, the ability of the 6 
carotid vasomotor response to predict CV events was independent of subject characteristics 7 
and more predictive than other common clinical measures such as ABPI and cIMT. This 8 
suggests that a measure of (generalised) vascular health is more important than the extent of 9 
the (localised) atherosclerotic lesion in PAD patients. Therefore, a simple and non-invasive 10 
measure of carotid artery endothelial function can identify PAD patients at increased risk for 11 
future adverse CV events and clinical progression.  12 
 13 
Dilation versus Constriction 14 
We14, 27 and others13, 15, 16 have demonstrated that the CPT produces a gradual dilator or 15 
constrictor response. Similarly, normal coronary arteries show an endothelium-mediated 16 
dilation that is mediated by the CPT-induced catecholamine-release, which exceeds the direct 17 
constrictor effects of catecholamines on smooth muscle cells.15, 16 However, endothelial 18 
dysfunction and/or (partial) endothelial damage impedes endothelium-mediated dilation 19 
leading to vasoconstriction.15 Similar responses in the carotid artery probably explain the 20 
distinct dilator or constrictor responses we observed in our study. Surprisingly, other subject 21 
characteristics, co-morbidities and clinical measures did not differ between PAD patients 22 
demonstrating constriction or dilator responses. This suggests that CV risk factors do not 23 
contribute to the distinct vasomotion responses between PAD patients, and that the PAD 24 
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disease state, rather than subject characteristics or CV risk factors contributes to carotid artery 1 
endothelial dysfunction. 2 
 3 
Relation between the carotid vascular response and subsequent events 4 
Current CV risk factors do not predict future CV events in patients with PAD.12 This 5 
highlights the potential utility of the carotid artery vasomotor response in predicting future 6 
CV events. Others have demonstrated that brachial artery flow-mediated dilation predicts 7 
future CV events in PAD patients,10, 11 but this technique is more difficult than our approach 8 
of simply measuring the relatively large carotid diameter (i.e. ~7.5 mm) in response to the 9 
CPT. Previous studies have also not measured clinical progression, whereas we found that 10 
carotid constriction had a 2-fold increased risk for loss of patency, endovascular 11 
reconstructive surgery and/or worsening in Fontaine-classification. This knowledge may 12 
allow clinicians to treat more aggressively in those patients at risk for clinical deterioration. 13 
 14 
Others have found that the coronary artery response to CPT predicts future CV events.17, 18  15 
Results from the present study suggest that the carotid artery response to the CPT is a 16 
surrogate for coronary arteries. This is supported by our previous within-subject observation 17 
that a subject’s carotid and coronary response to the CPT are similar.14, 27 This observation 18 
also supports the concept that atherosclerosis is a whole body, generalised disease of the 19 
endothelium, such that an abnormal response in one vascular bed is likely also present other 20 
vascular beds. Consistent with this concept is the observation that abnormal brachial artery 21 
dilator responses to endothelial stimulation using increased flow6 or acetylcholine28 are 22 
associated with abnormal coronary artery responses to endothelial stimulation. 23 
 24 
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ABPI is useful in both the diagnosis of PAD29 and predicting the need for revascularisation.2, 1 
30, 31
 Examining cIMT has also been useful in predicting atherosclerotic risk in some, but not 2 
all, studies of the general population.24, 32 We found no relation between either ABPI or cIMT 3 
and future CV events, clinical progression or adverse events. Furthermore, adding these 4 
clinical measures to the statistical model did not alter the relationship between carotid artery 5 
reactivity and future (CV) events. The finding that ABPI and cIMT are not related to future 6 
events contrasts with previous work performed in the general population,2, 30, 31 but is largely 7 
in agreement with studies performed in PAD.12, 33 Abnormal ABPI and cIMT indicate the 8 
presence of atherosclerosis, whereas coronary responses to CPT reflect endothelial function.  9 
This suggests that in individuals with known CVD, the impact of the atherosclerotic process 10 
on the endothelium is more important than the atherosclerotic lesion in predicting CV events.  11 
 12 
A potential limitation of our study is that we did not include other biomarkers, such as high-13 
sensitive C-reactive protein, which are demonstrated to have potential prognostic value in 14 
PAD for future CV events.37, 38 Unfortunately, we did not assess these biomarkers to examine 15 
the potential added value of combining these markers with the CAR, which may be relevant 16 
since these biomarkers may provide additional information to our in vivo measure of 17 
endothelial function. 18 
 19 
Clinical relevance. The carotid artery reactivity to CPT procedure is easy to perform, low-20 
cost, non-invasive, and requires minimal time and equipment. The simplicity of the test is 21 
supported by an excellent reproducibility.14 Moreover, in contrast to the majority of subject 22 
and/or disease characteristics, the carotid artery vasomotor response to CPT identified 23 
subjects with an increased risk for future events. The clinical relevance of the CAR may relate 24 
the identification of PAD patients who are more vulnerable to non-adherence and/or 25 
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complications during surgery. For example, although symptomatic PAD should all be on drug 1 
therapy, compliance to therapy is relatively poor.34-36 The CAR-test may help to identify 2 
individuals in whom it is of special importance to maintain compliance to drug therapy. 3 
Additionally, cardiovascular co-morbidity in PAD patients is associated with increased 4 
perioperative cardiovascular risk. Future studies are needed to assess the potential added 5 
value of the CAR to estimate perioperative risk in PAD patients.  6 
 7 
In conclusion, our study provides the first evidence that carotid artery reactivity, independent 8 
of subject characteristics and clinical measures such as cIMT and ABPI, predicts future 9 
adverse (CV) events and clinical progression in PAD patients. The presence of carotid artery 10 
constriction during the CPT is associated with a 4-fold increased risk for future CV events 11 
and 2-fold increased risk for clinical progression. These observations suggest that the carotid 12 
artery reactivity should be further evaluated for its ability to predict future risk in patients 13 
with PAD.  14 
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FIGURES. 1 
FIGURE 1.  CONSORT diagram of the study. 2 
FIGURE 2.  Set-up of the practical performance of the test (A). Screen-shot of the 3 
assessment of carotid artery diameter, with the yellow box indicating the region of interest 4 
within the automated software performed analysis of the diameter (i.e. yellow lines on the 5 
artery wall) (B). Data from a representative subjects demonstrating carotid artery diameter 6 
dilatation (C) and constriction (D) during the cold pressor test. Both panels represent the 7 
carotid artery diameter (in cm) across the 30-s baseline (up to the vertical dashed line; the 8 
start of the cold pressor test) and 90-s during the cold pressor test. Data were analysed in 10-9 
second bins to identify presence of dilatation or constriction. More detailed findings of this 10 
procedure is presented in the methods section. 11 
FIGURE 3. Kaplan-Meier survival curves for adverse events (A), CV events (B), clinical 12 
progression (C) and all-cause mortality (D) in PAD patients (n=172) across a 1-year follow-13 
up. We have dichotomised PAD patients in those who demonstrate coronary constriction 14 
(CAR constriction, dotted line) or dilation during the CPT (CAR dilation, solid line). P-values 15 
relates to a Log-rank test.   16 
FIGURE 4. Kaplan-Meier survival curves for cIMT (A, 169 PAD patients), and ABPI (B, 17 
142 PAD patients) related to occurrence of adverse events across a 1-year follow-up. The 18 
solid line represents the cIMT and ABPI above the median, the dotted line refers to the cIMT 19 
and ABPI below the median. P-values relates to a Log-rank test. 20 
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Table 1. Baseline characteristics of patients with PAD with carotid artery constriction (CAR 1 
constriction) or dilation (CAR dilation) during the CPT. *Indicate Mann-Whitney U test, 2 
presented as median [minimum – maximum]. P-value indicates difference between 3 
vasoconstriction versus vasodilation.  4 
 
Total group CAR constriction CAR dilation P-value 
Subject characteristics n=172 n=82 n=90 
 
Age*, y 68±10 71 [43-85] 67 [46-90] 0.223 
Sex, males (%) 115 (67) 58 (71) 57 (63) 0.303 
Height (m) 1.73±0.09 1.73±0.10 1.72±0.10 0.464 
Weight (kg) 79.8±14.6 80.1±14.3 79.6±14.9 0.804 
Body-mass index (kg/m2) 27±4 27±4 27±4 0.900 
Waist-to-hip ratio 1.01±0.10 1.02±0.10 1.00±0.10 0.210 
Smoking, yes n (%) 55 (32) 28 (34) 27 (30) 
 
   History n (%) 97 (56) 45 (55) 52 (58) 0.839 
Comorbidities 
Hypertension, n (%) 
 
 
138 (80) 
 
 
66 (80) 
 
 
72 (80) 
 
 
0.936 
Hypercholesterolemia, n (%)  133 (76) 61 (74) 72 (80) 0.380 
Diabetes Mellitus, n (%) 46 (27) 22 (27) 24 (27) 0.873 
 
Medication use 
Antiplatelet drugs, n (%) 
 
 
135 (78) 
 
 
58 (71) 
 
 
77 (86)  0.018 
 
0.667 
  Acetylsalicylic acid (ASA) 125 (73) 55 (67) 70 (78) 
  Plavix (clopidogrel) 4 (2) 1 (1) 3 (3) 
  Dual therapy (combined) 6 (3) 2 (2) 4 (4) 
Statins, n (%) 141 (82) 71 (87) 70 (78) 0.133 
Beta-blockers, n (%) 89 (52) 40 (49) 49 (54) 0.458 
ACE inhibitors, n (%) 59 (34) 26 (32) 33 (37) 0.494 
Proton pump inhibitors, n (%) 87 (51) 40 (49) 47 (52) 0.652 
 
Clinical status 
Mild ischaemia  
(Fontaine 1-2A), n (%) 
 
 
62 (36) 
 
 
25 (30) 
 
 
37 (41) 
 
 
0.143 Moderate-severe ischaemia 
(Fontaine 2B-3-4), n (%) 110 (64) 57 (70) 53 (59) 
ABPI (n=142) 0.65±0.22 0.65±0.22 0.66±0.21 0.679 
ABI left rest (n=135) 0.72±0.22 0.73±0.21 0.76±0.25 0.402 
ABI right rest (n=132) 0.73±0.22 0.74±0.25 0.74±0.21 0.978 
Carotid IMT* (mm) 0.79 [0.15-2.78] 0.80 [0.15-2.78] 0.78 [0.35-2.06] 0.860 
Baseline carotid diameter* (mm) 7.5±1.1 7.7 [4.4-10.5] 7.3 [5.1-10.9] 0.358 
CAR% 0.8 [-19.3 - 11.6] 1.3 [-9.5 – 11.6] -1.2 [-19.3 – 9.6] 0.068* 
 5 
  6 
Van Mil et al. CAR in PAD patients 
23 
 
Figure 1 1 
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Figure 2 1 
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Figure 3 1 
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